Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# FOMAT: Clinical trials embedded at point of care

## Sitemaps
[XML Sitemap](https://fomatmedical.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Cancer Trial Prescreening Gets a Boost Through FOMAT and Massive Bio Partnership](https://fomatmedical.com/company-updates/cancer-trial-prescreening/): Cancer trial prescreening is one of the biggest bottlenecks between a cancer diagnosis and access to a potentially life changing study. FOMAT has partnered with Massive Bio to close that gap, combining Massive Bio's AI driven patient matching technology with FOMAT's embedded research infrastructure to give oncology patients a faster, more direct path from prescreening to enrollment.
- [Embedded Clinical Trials: 7 Top Partners for 2026](https://fomatmedical.com/blogs-updates/embedded-clinical-trials-partners/): Embedded clinical trials are becoming the standard model for sponsors who need Phase II and III studies to run inside the places patients already receive care, rather than inside a standalone research building. For pharmaceutical sponsors and CRO clinical operations leaders, choosing the right embedded clinical trials partner determines whether a study hits its enrollment timeline or falls behind it.
- [How to Build Diverse Trial Recruitment in 2026](https://fomatmedical.com/blogs-updates/community-based-model/): A community based model is what separates sponsors that hit their 2026 diversity targets from sponsors that fall behind. Investing in a community based model, paired with multilingual and data driven support, is how sponsors and CROs actually hit diverse enrollment targets. This guide breaks down why most recruitment plans stall, and what a proper community based model looks like inside a single embedded network of clinical trial services.
- [What Makes Diverse Trial Recruitment Hard for Sponsors](https://fomatmedical.com/blogs-updates/clinical-research-recruitment/): Clinical research recruitment in diverse communities is one of the most cited challenges in clinical research and one of the most consistently underfixed. For pharmaceutical sponsors and CROs managing timelines, enrollment targets, and regulatory requirements, clinical trial patient recruitment in diverse populations is not just a DEI priority. It is a scientific and operational necessity that directly affects your data quality, FDA review, and post-market labeling.
- [Phase II and III Trials: Top Clinical Service Partners for 2026](https://fomatmedical.com/blogs-updates/phase-ii-and-iii-trial-service-partners/): A practical guide for pharmaceutical sponsors and biotech clinical operations leaders evaluating phase II and III trial service partners for oncology, complex site activation, and quality management programs.
- [Sponsor Recruitment Support: How to Expand Trial Access Through Community Clinics](https://fomatmedical.com/blogs-updates/sponsor-recruitment-support/): A definitive guide for pharmaceutical sponsors and CRO clinical operations leaders on building sponsor recruitment support infrastructure through community clinic partnerships, embedded research models, and diverse patient enrollment strategies.
- [9 Patient Recruitment Services for Community Clinics](https://fomatmedical.com/blogs-updates/recruitment-community-clinic-trials/): Community clinic trials represent one of the most underutilized strategies for sponsors seeking faster enrollment, broader diversity, and stronger real world data. Yet more than 80% of clinical trials fail to meet their original enrollment timelines, and a significant share of that failure traces back to a fundamental site selection problem: trials are predominantly placed at academic medical centers that do not reflect the demographics of the patients most affected by the diseases being studied.
- [How Embedded Clinical Research Improves Trial Data Quality and Enrollment](https://fomatmedical.com/blogs-updates/embedded-clinical-research-data/): When a clinical trial fails to enroll on time, the problem rarely starts with recruitment. It starts with the distance between where patients receive care and where research happens. Traditional site models ask patients to travel to separate facilities, follow separate schedules, and see separate physicians — models that embedded clinical research was designed to replace. That friction compounds at every step, and it shows up in the data.
- [How to Fix Patient Recruitment Bottlenecks in Trials](https://fomatmedical.com/blogs-updates/patient-recruitment-bottlenecks-phase-2-3/): Few problems cost sponsors more time and money than patient recruitment bottlenecks in Phase II and III trials. A study that cannot enroll on schedule delays first patient in, pushes back database lock, and threatens the entire development timeline. For clinical development and clinical operations leaders at pharmaceutical sponsors and CROs, understanding where these bottlenecks form, and how to clear them, is one of the highest leverage skills in the field. This guide breaks down the root causes of recruitment and retention failure, and shows how community based, diverse enrollment models reduce both delays and dropout risk.
- [Why Diverse Patient Recruitment Matters in Trials](https://fomatmedical.com/blogs-updates/diverse-clinical-trial-patient-recruitment/): Recruitment and retention remain the two hardest problems in clinical research, and they are getting harder. For pharmaceutical sponsors and CRO clinical operations leaders running Phase II and III studies, weak clinical trial patient recruitment delays timelines, inflates costs, and produces data that fails to reflect the populations a therapy is meant to serve. When recruitment skews toward a narrow demographic, regulators question generalizability and the entire program slows down. This article breaks down why sponsors struggle with diverse enrollment and retention, and how a community based, patient centered model fixes both.
- [Where Oncology Trials Stall: 7 Partners That Get Sites Live Faster](https://fomatmedical.com/blogs-updates/oncology-site-activation-partners/): In oncology, the gap between a signed contract and a fully activated site is where timelines quietly slip away. For pharmaceutical sponsors, CRO leaders, and biotech clinical operations teams running Phase II and III cancer studies, oncology site activation is one of the highest stakes phases of the entire trial. Slow activation delays first patient in, inflates costs, and puts enrollment targets at risk before recruitment even begins. This ranked guide highlights seven partner profiles that stand out for disciplined quality management and the ability to activate complex oncology sites without sacrificing data integrity.
- [Top Oncology Clinical Trial Site Partners for Biotechs](https://fomatmedical.com/blogs-updates/oncology-clinical-trial-site-partners/): Choosing the right oncology clinical trial site can determine whether a study enrolls on time, retains patients, and produces clean data that holds up to regulatory scrutiny. For pharmaceutical sponsors and biotech clinical operations leaders, the decision goes far beyond geography. It comes down to quality management, real access to diverse patient populations, and a track record of executing complex cancer protocols without costly delays. This ranked guide breaks down what separates a high-performing oncology clinical trial site from one that drains timelines and budgets.
- [Clinical Trial Patient Recruitment in Phase II and III](https://fomatmedical.com/blogs-updates/patient-recruitment-in-clinical-trials/): Phase II and III trials are where sponsors commit the most time, capital, and scientific reputation, yet they are also where participant loss does the most damage. A study that enrolls slowly or bleeds participants midway through dosing can push timelines back by months and put statistical power at risk. Strong patient recruitment in clinical trials is not a single launch event. It is a continuous effort that runs from first outreach through the final follow-up visit, and the sponsors who treat it that way protect both their data and their budgets.
- [Improve Patient Retention in Phase II III Trials](https://fomatmedical.com/blogs-updates/patient-retention-in-clinical-trials/): Retention is where many Phase II and III studies quietly lose ground, and it almost always traces back to how the study began. Strong patient retention in clinical trials depends less on chasing dropouts and more on building continuity from the first visit. For sponsors and CRO clinical operations leaders, understanding why retention breaks down in community based trials, and how recruitment shapes it, is the first step toward steadier enrollment curves and cleaner data. The studies that hold their cohorts together are rarely lucky; they are designed for continuity from the moment the first participant signs a consent form, and that design decision pays off every month the trial runs.
- [What Embedded Research Means for Clinical Trials](https://fomatmedical.com/blogs-updates/embedded-research-in-clinical-trials/): The way sponsors design enrollment is shifting, and embedded research in clinical trials sits at the center of that change. Rather than asking patients to travel to dedicated research facilities, this approach folds studies into the everyday practices where people already see their doctors. For pharmaceutical sponsors and CRO clinical operations leaders, knowing how embedded research in clinical trials works, and how it diverges from conventional site networks, is fast becoming part of sound trial planning.
- [How Recruitment Models Are Reshaping Biotech Trial Enrollment](https://fomatmedical.com/blogs-updates/biotech-trial-recruitment-services/): Biotech trial recruitment has become the deciding factor in whether a study finishes on time or stalls in startup. For sponsors and clinical operations leaders, the question is no longer whether to outsource recruitment but which model actually reaches the patients who need access to trials. Below are seven service models shaping biotech trial recruitment across the US, with a focus on community based access and the embedded research approach that increasingly defines competitive enrollment.
- [How Clinical Trial Data Quality Improves Across Phase I, II, and III](https://fomatmedical.com/blogs-updates/clinical-trial-data-quality/): Clinical trial data quality is essential to every successful clinical study. Accurate, timely, and inspection-ready information allows sponsors and CROs to evaluate safety, study performance, and clinical outcomes with confidence.
- [How Embedded Research Models Improve Trial Enrollment](https://fomatmedical.com/blogs-updates/embedded-research-models/): Embedded research models address this gap by integrating clinical research directly into community healthcare settings. Rather than asking patients and physicians to navigate a separate research ecosystem, these models make study participation part of an existing care journey.
- [Language Barriers in Clinical Trial Recruitment](https://fomatmedical.com/blogs-updates/patient-recruitment-challenges/): Language differences are among the most persistent patient recruitment challenges in community-based clinical research.
- [Top Clinical Trial Service Partners for Sponsors in 2026](https://fomatmedical.com/blogs-updates/clinical-trial-service-partners/): Selecting the right clinical trial service partners can influence site activation, patient recruitment, quality, regulatory readiness, and overall study performance.
- [Patient Recruitment for Community-Based U.S. Trials](https://fomatmedical.com/blogs-updates/patient-recruitment-services-diverse-us-trials/): Community-based patient recruitment services bring these elements together by placing clinical research within the healthcare settings where patients already receive care.
- [What Site Management Organizations Do in U.S. Clinical Trials](https://fomatmedical.com/blogs-updates/site-management-organizations-us-trials/): Coordinating these responsibilities across multiple locations can create a significant operational burden for pharmaceutical sponsors and CROs. For sponsors and CROs, site management organizations can reduce operational fragmentation across research locations by providing centralized systems, personnel, processes, and accountability.
- [Site Management Organizations for Clinical Trials: 7 Capabilities](https://fomatmedical.com/blogs-updates/site-management-organizations-for-clinical-trials/): However, not all site management organizations for clinical trials provide the same level of infrastructure, patient access, or operational support.
- [How to Evaluate Embedded Research Partners in U.S. Community Care](https://fomatmedical.com/blogs-updates/embedded-research-partners/): Embedded research partners provide the infrastructure, personnel, systems, and operational support required to conduct clinical trials within existing healthcare practices.
- [Why Clinical Trial Recruitment Is Hard for Sponsors](https://fomatmedical.com/blogs-updates/clinical-trial-patient-recruitment/): Clinical trial patient recruitment remains one of the most persistent operational challenges for pharmaceutical sponsors, biotechnology companies, and CROs.
- [Community Clinic Participation in Clinical Trials: The Proven 2026 Guide](https://fomatmedical.com/blogs-updates/community-clinic-participation-trials-2026/): Community clinic participation is redefining what effective clinical trial recruitment looks like in the United States. Sponsors who once defaulted to academic medical centers and standalone research facilities are now recognizing a fundamental truth: the patients who need access to trials are not sitting in university hospitals. They are in community clinics, specialty practices, and regional health systems across the country, and reaching them requires a different model entirely.
- [Best Patient Recruitment Services for Community Trials](https://fomatmedical.com/blogs-updates/patient-recruitment-services-community-trials/): For U.S. sponsors, biotech teams, and CRO leaders, selecting the right patient recruitment services is one of the highest-stakes decisions in clinical development. Enrollment delays are the leading cause of trial budget overruns, and the traditional site models that have long dominated the industry are increasingly unable to deliver the speed, diversity, and retention that modern trials require.
- [Best Oncology Trial Management Providers in 2026](https://fomatmedical.com/blogs-updates/oncology-trial-management-providers/): Oncology trial management demands a level of operational precision that separates generalist site networks from organizations built specifically for cancer research. Patient populations are medically complex, protocols are lengthy, dropout risk is high, and the regulatory bar for Phase I dose-escalation studies is unforgiving. Sponsors and CROs selecting partners for oncology programs need more than site count — they need community access, Phase I infrastructure, and a track record in diverse patient populations.
- [Top U.S. Clinical Trial Site Networks for Diverse Patient Access](https://fomatmedical.com/blogs-updates/clinical-trial-site-networks/): Clinical trial site networks are one of the most consequential decisions in study planning. Beyond regulatory compliance and infrastructure, sponsors and CROs increasingly evaluate a network's ability to enroll diverse patient populations — a priority driven by FDA guidance, payer expectations, and scientific validity.
- [What Is Diverse Patient Recruitment in Clinical Trials](https://fomatmedical.com/blogs-updates/diverse-patient-recruitment-clinical-trials/): Diverse patient recruitment is one of the biggest challenges in clinical research today. And it's one that clinical trial services are uniquely positioned to solve. Here's what it means, why it matters, and how it actually works in practice.
- [Clinical trial services: the smarter hybrid CRO model for Phase 3](https://fomatmedical.com/blogs-updates/clinical-trial-services-hybrid-cro/): Clinical trial services for multi-site Phase 3 studies have evolved far beyond the traditional "build or buy" decision — and the hybrid insourced CRO model is leading that shift.
- [Top Clinical Trial Services for Biotech Sponsors: What to Look For and What to Ask](https://fomatmedical.com/blogs-updates/clinical-trial-partner-for-biotech/): Biotech sponsors evaluating a clinical trial partner for biotech programs face a crowded market. The right partner can mean the difference between hitting enrollment targets on schedule and watching timelines slip. This guide breaks down what to look for when selecting a full-service clinical trial partner for Phase I through Phase III programs — and the questions every biotech sponsor should ask before signing.
- [The 6 criteria that define a top clinical research network](https://fomatmedical.com/blogs-updates/top-clinical-research-site-network/): Not all clinical research networks are built the same. Sponsors and CROs evaluating site networks — and patients looking for access to cutting-edge treatments — need to understand what separates a high-performing network from an average one. This article breaks down the criteria that define the top clinical research site networks in the US, and where FOMAT stands against each one.
- [Site Management Organization: 4 Proven Models That Shaped Clinical Research](https://fomatmedical.com/company-updates/site-management-organization/): The site management organization did not appear out of nowhere. It was a direct response to a structural problem that the clinical research industry had spent decades making worse, and the site management organization was the solution that finally stuck.
- [FOMAT Medical Research: Largest Proven Embedded Research Organization in the US](https://fomatmedical.com/company-updates/fomat-medical-research-ero/): FOMAT Medical Research is an Embedded Research Organization (ERO) headquartered in Oxnard, California, operating a national network of clinical trial sites across the United States. Founded in 2013, FOMAT has spent more than a decade embedding clinical trials directly into active community physician practices, bringing research to patients where they already receive care.
- [FOMAT Acquires Topography Health: A Conversation With CEO Nick Focil](https://fomatmedical.com/company-updates/fomat-acquires-topography-health/): At the recent MAGI Clinical Research Conference, Clinical Leader editor Dan Schell crossed paths with Nick Focil, CEO of FOMAT Medical Research. Over dinner with a small group, Focil hinted that something big was coming for FOMAT, but stopped short of sharing details. A few weeks later, a Zoom call revealed everything: FOMAT acquires Topography Health, adding 10 new locations across six states.
- [FOMAT Acquires Topography Health and Becomes the Largest Embedded Research Organization in the U.S.](https://fomatmedical.com/company-updates/embedded-research-organization-fomat/): FOMAT has acquired Topography Health, expanding its national network to more than 35 investigator sites across six states — Maryland, California, Colorado, New Mexico, Michigan, and Virginia. With this acquisition, FOMAT becomes the largest Embedded Research Organization (ERO) in the United States.
- [Common Endocrine Disorders and How to Treat Them](https://fomatmedical.com/blogs-updates/common-endocrine-disorders/): Endocrine disorders are more common than you think. Millions of people live with conditions like diabetes, thyroid disease or polycystic ovary syndrome (PCOS) without even knowing what’s behind their symptoms. In this blog, we’ll explore the most common endocrine disorders, what causes them, how they’re treated and how advances in endocrine disorder treatment can help you take control of your health.
- [Why Regular Tests Matter for Detecting Hypertriglyceridemia Early](https://fomatmedical.com/blogs-updates/hypertriglyceridemia-early-detection/): We view blood tests as routine, a standard part of annual checkups that we rarely question. But these simple tests can reveal so much about our health, often before symptoms appear. One of the most silent yet significant findings that can pop up on a blood test is hypertriglyceridemia, or high triglyceride levels in the blood.
- [What Recent Research and Clinical Trials Teach Us About Thyroid Disease and Its Impact on Your Health](https://fomatmedical.com/blogs-updates/gut-microbiome-metabolic-health/): Imagine a busy city inside your body, filled with trillions of microscopic inhabitants working around the clock. This is the makeup of your gut microbiome, a complex community of microorganisms living in your digestive system. These tiny residents play a big role in your overall health, especially in how your body manages weight, blood sugar and fat. In this blog, we’ll dive into the world of the gut microbiome and how it relates to metabolic conditions like obesity and type 2 diabetes.
- [A Breakthrough in Liver Health Means New Hope for Liver Disease Clinical Trials and Treatment](https://fomatmedical.com/blogs-updates/liver-disease-clinical-trials/): When we think of vital organs, the liver might not be the first that comes to mind. But it actually does a lot of the heavy lifting when it comes to keeping us alive. The liver is responsible for processing nutrients, filtering toxins, producing hormones and supporting digestion. Yet, when something goes wrong in the liver, liver disease clinical trials are now offering new hope for patients who need it most. FOMAT is currently enrolling patients in liver disease clinical trials across our site network.
- [The Obstacles and Promise in Endocrine-Related Cancers](https://fomatmedical.com/blogs-updates/endocrine-related-cancers-trials/): Cancer is a complicated disease and research is constantly changing our understanding of it. One of the latest is endocrine-related cancers (ERCs), cancers driven by hormones. Breast and prostate cancer have been hormone-driven for ages, but research is showing hormones may be involved in many other cancers, too.
- [Your Gut, Your Health: How Microbes in Your Stomach Impact Metabolic Disease Risk](https://fomatmedical.com/blogs-updates/gut-microbiome-and-obesity/): Your gut microbiome is an intricate community of microorganisms living in your digestive system. These microbes impact everything from digestion to immune function and even weight management. Let’s dive in and see how your gut microbiome affects metabolic diseases like obesity and type 2 diabetes and what you can do to keep it in top shape.
- [Hispanic Community Perspectives on Clinical Trial Participation](https://fomatmedical.com/company-updates/hispanic-community-perspectives-on-clinical-trial-participation/): Hispanic clinical trial participation remains critically low despite being one of the fastest-growing demographic groups in the U.S. This gap not only limits the generalizability of research findings, but also deepens existing healthcare disparities.
- [Expanding Ophthalmology Clinical Trials in Central California](https://fomatmedical.com/company-updates/ophthalmology-clinical-trials-ca/): FOMAT is expanding its ophthalmology clinical trials network in Central California through a new partnership with Dr. Daniel R. Agarwal, an ophthalmologist specializing in retina and vitreous care at San Luis Obispo Eye Associates. This collaboration reflects FOMAT's commitment to bringing innovative therapies to underserved regions and diverse patient populations across the state. Ophthalmology clinical trials represent a critical frontier in addressing eye conditions that affect millions of patients worldwide, and FOMAT is positioned to lead this effort in Central California.
- [Why Children Need Dedicated Pediatric Vaccination Studies](https://fomatmedical.com/blogs-updates/pediatric-vaccination-studies/): Pediatric vaccination studies are the foundation of everything we know about keeping children safe from serious disease. From common illnesses like the flu to life-threatening conditions like polio, vaccines have saved an estimated 2 to 3 million lives worldwide every year. But how do we ensure these vaccines are safe and effective for kids? That’s where pediatric vaccination medical studies come in.
- [Advancements in the Treatment of Endocrine Disorders](https://fomatmedical.com/blogs-updates/endocrine-disorder-treatment/): Endocrine disorder treatment is evolving rapidly as advances in technology, personalized medicine, and clinical research open new pathways for managing hormonal and metabolic conditions. The human body relies on the endocrine system to regulate hormones that control growth, energy, metabolism, reproduction, and mood. When this system is disrupted, conditions like diabetes, thyroid disorders, and polycystic ovary syndrome (PCOS) can develop — affecting millions of people worldwide and placing a significant burden on healthcare systems globally.
- [FOMAT Medical Research Expands to Santa Maria, California, Strengthening Regional Access to Clinical Research](https://fomatmedical.com/company-updates/clinical-research-in-santa-maria/): FOMAT has opened a new hub, making clinical research in Santa Maria, California more accessible than ever for underserved communities in the region. Building on years of active research presence in the area, this expansion strengthens the organization's capacity to connect residents with innovative treatment options through Phase I through Phase IV clinical trials. The move reflects FOMAT's broader commitment to addressing healthcare disparities by bringing research directly to the populations that need it most.
- [What Hypertriglyceridemia Clinical Trials Are Teaching Us About Triglyceride-Lowering Medications](https://fomatmedical.com/blogs-updates/hypertriglyceridemia-clinical-trials/): Hypertriglyceridemia clinical trials are teaching researchers and clinicians more than ever about how to manage high triglyceride levels and reduce the serious health risks they carry. Hypertriglyceridemia occurs when triglyceride levels exceed 150 mg/dL, creating elevated risks for cardiovascular disease, acute pancreatitis, and metabolic disorders. Thanks to ongoing research, we now have a clearer picture of which treatments work, for whom, and why.
- [How Precision Medicine and Obesity Trials are Changing Treatment Options](https://fomatmedical.com/blogs-updates/obesity-clinical-trials-precision-medicine/): Obesity clinical trials are at the forefront of a major transformation in how we understand and treat one of the world's most pressing public health challenges. Obesity is rising globally at an alarming rate, and its health consequences are significant — a high body mass index (BMI) is a major risk factor for cardiovascular disease, diabetes, chronic kidney disease, various cancers, and musculoskeletal disorders. Precision medicine is changing how these conditions are managed, and obesity clinical trials are the engine driving that change.

## Pages
- [Cancer Clinical Trials](https://fomatmedical.com/cancer-clinical-trials-in-california/): Cancer clinical trials in California are open right now at FOMAT Medical. Most people with a diagnosis focus on what their doctor already recommends. That makes sense. But most patients never think to ask about this option.
- [Capital Digestive Care Studies](https://fomatmedical.com/clinical-studies-capital-digestive-care/): Join our community of patients contributing to the future of digestive health. View current studies and check your eligibility today
- [Welcome Aboard](https://fomatmedical.com/welcome-aboard/): Thank you for joining us. Please use this page to share the details we need to support your onboarding.
- [Oncology](https://fomatmedical.com/oncology-clinical-trial/): Our oncology clinical trial capabilities include advanced imaging and diagnostics access, experienced research teams, and tailored operational support across phases. We ensure consistent trial delivery with specialized infrastructure and reliable execution for complex oncology protocols.
- [Ophthalmology and Retina](https://fomatmedical.com/ophthalmology-and-retina/): Our ophthalmology and retina clinical trial capabilities include advanced imaging readiness, experienced research teams, and tailored operational support across study phases. We ensure consistent trial delivery with established patient relationships and retina focused workflows aligned to endpoint heavy protocols
- [Infectious Diseases / Vaccine](https://fomatmedical.com/infectious-diseases-vaccine/): FOMAT Prime Therapeutic Areas provide highly specialized research sites with robust infrastructure, experienced investigators, and proven recruitment models. In Infectious Diseases & Vaccines, we support trials targeting viral infections, bacterial diseases, and immunizations with advanced diagnostics and access to diverse populations 0 % 0 0 0 + Our infectious disease trial capabilities include state-of-the-art laboratory and testing equipment, experienced clinical research teams, and reliable operational support across all trial phases. We ensure consistent trial delivery with access to diverse pediatric and adult patient population Full on-site diagnostic suite (PCR, ELISA, Flow Cytometry, Hematology Analyzers, Rapid Test Kits)Dedicated SOPs and quality control processes for Digestive studiesMulti-location patient access across California research sitesIntegrated EHR, CTMS, eSource, eConsent, and remote monitoring systemsSpecialized community engagement and recruitment teams targeting pediatric, adult, and senior populationsExperienced research teams trained in infectious disease protocols and vaccine development
- [Nephrology](https://fomatmedical.com/nephrology/): Our nephrology trial capabilities include integrated diagnostic and monitoring equipment, experienced clinical research teams, and reliable operational support. We enable consistent trial delivery through coordinated clinical operations and patient centered engagement.
- [Cardiovascular and Circulatory Diseases](https://fomatmedical.com/cardiovascular-and-circulatory-diseases/): Our cardiovascular trial capabilities include integrated monitoring and diagnostic access, experienced clinical research teams, and reliable operational support. We ensure consistent trial delivery with standardized processes and strong patient reach across cardiovascular populations.
- [Patient Recruitment Excellence](https://fomatmedical.com/patient-recruitment-excellence/): Research takes place in active clinics and community practices. Physicians and staff know the local population and our bilingual teams manage education, prescreening and scheduling in the language people prefer.
- [Endocrinology and Metabolic](https://fomatmedical.com/endocrinology-clinical-trials/): FOMAT Prime Therapeutic Areas provide highly specialized research sites with strong infrastructure, expert investigators, and proven recruitment models. In Endocrinology and Metabolic Disease, we support trials across NAFLD, MASH, obesity, diabetes, and related conditions with full diagnostic capabilities and access to diverse patients 0 % 0 0 0 Our endocrinology clinical trials infrastructure is designed to handle complex protocols with consistency, making FOMAT a trusted partner for sponsors seeking operational efficiency Dedicated SOPs and quality control processes for Endocrinology studiesExperienced staff managing metabolic trials across NAFLD, MASH, obesity, and diabetesMulti-location patient access across California clinical sitesIntegrated EHR, CTMS, eSource, eConsent, and remote monitoring systemsSpecialized community engagement and recruitment teams targeting metabolic populations
- [Digestive Diseases](https://fomatmedical.com/digestive-diseases/): FOMAT Prime Therapeutic Areas provide highly specialized research sites with strong infrastructure, expert investigators, and proven recruitment models. In Digestive Diseases, we support trials across NAFLD, MASH, IBD, GERD, and related conditions with full diagnostic capabilities and access to diverse patients
- [Quality and Compliance](https://fomatmedical.com/quality-and-compliance/): Dedicated quality teamsIn-house Quality and Compliance specialists support all studies and locations.
- [Providers](https://fomatmedical.com/physician-investigator-network/): Contact us to discuss your practice, research goals, and next steps to join our investigator network.
- [Diversity](https://fomatmedical.com/diversity-in-clinical-trials/): Our sites, teams and recruitment pathways are designed to reach people who are usually underrepresented in clinical research. The result is data that better reflects everyday patients and their realities.
- [What are clinical trials](https://fomatmedical.com/patient-what-are-clinical-trials/): Clinical trials are research studies that test new treatments, medicines, or medical approaches to see if they are safe and effective. They help doctors and scientists improve patient care and find better ways to prevent, diagnose, and treat diseases.
- [Phase II – III Capabilities](https://fomatmedical.com/phase-ii-iii-capabilities/): Phase II to III studies are delivered through an embedded model that connects community based medical practices, EMR based pre screening and centralized operations under one coordinated structure.
- [Upcoming Events](https://fomatmedical.com/events/): View our upcoming conference schedule and contact us to arrange a meeting with our team.
- [Phase I Capabilities](https://fomatmedical.com/phase-i-capabilities/): A dedicated Phase I unit embedded in active care settings, equipped to run complex Phase I studies with close follow up, rapid decisions, and reliable data.
- [Participant Stories](https://fomatmedical.com/clinical-research-stories/): Hear how research became part of their care and everyday life, and what it could mean for you and your family.
- [About us](https://fomatmedical.com/about-fomat/): FOMAT, headquartered in California, is an Embedded Research Organization with over a decade of experience in diversifying clinical trials. We provide a broad range of services to empower principal investigators, fuel healthcare innovation and advance new treatments, guided by strong ethical standards and data quality.
- [Company Updates](https://fomatmedical.com/company-updates/): Stay informed about FOMAT initiatives, new capabilities, awards and other key news.
- [Home Fomat](https://fomatmedical.com/): Join FOMAT network. Let’s collaborate to bring clinical research as an option to your organization
- [Contact](https://fomatmedical.com/contact-fomat/): 300 South A Street, Suite 201 Oxnard, CA 93030(805) 483-1185
- [Blogs & Updates](https://fomatmedical.com/blogs-updates/): Our blogs explain health conditions and clinical research in a way that is easy to follow, so readers can feel more informed
- [Careers](https://fomatmedical.com/careers/): Join FOMAT and contribute to clinical research across our organization. Your work helps promising studies move forward and brings better treatment options closer to people who need them.
- [Privacy Policy](https://fomatmedical.com/privacy-policy/): 1. Data FOMAT May Collect